Navigation Links
University of Colorado Cancer Center earns major grant to develop new bladder cancer drugs
Date:8/15/2012

Bladder cancer kills by metastasizing usually to the lungs. A major grant from the National Cancer Institute will help the University of Colorado Cancer Center develop new drugs aimed at stopping bladder cancer's spread, which will kill an estimated 15,000 people in the United States this year.

"Strong preliminary work shows specific proteins that bladder cancer cells need in order to leave the bladder and attach to lung tissue. And additional work points to a number of drug candidates that block the activity of these proteins. The current project aims to select the best drug, use medicinal chemistry to boost its effectiveness, and move the optimized drug toward a human clinical trial," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center, who will co-lead the project with David Ross, PhD, chair of the Department of Pharmaceutical Sciences at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado.

The work is especially important in light of two current conditions: first, the extended absence of new drugs targeting bladder cancer, with the most recent advance being the addition of the drug gemcitabine, which earned FDA approval in 1997; and second, the recent explosion of technologies that allow the development of drugs that target a cancer's specific genetic abnormalities.

"We've seen a paradigm shift toward targeted therapies drugs that unlike the traditional chemotherapies selectively kill cancer cells while leaving healthy tissue unharmed. We hope to apply this paradigm to metastatic bladder cancer," says Colin Dinney, MD, co-principal investigator and chair of the Department of Urology at project partner MD Anderson.

"This project will target metastatic colonization in bladder cancer by targeting the proteins that drive these processes," says David McConkey, PhD, co-principal investigator at MD Anderson.

"We also hope to define the biomarkers of patients likely to respond to the drugs," Theodorescu says. Defining the population most likely to benefit from the new drugs would allow the group to select these patients for Phase I clinical trials the project's intended endpoint.

"We are all hopeful that three years from now, we'll have a drug in clinical trials that prevents or delays the development of metastatic disease high-risk patients following treatment of the primary tumor," Theodorescu says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Hospital of the University of Pennsylvania selected to lead US nurse-training initiative
2. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
3. Boston University researchers expand synthetic biologys toolkit
4. Canadians super-sizing Canadas Food Guide servings: York University study
5. Tel Aviv University researcher says plants can see, smell, feel, and taste
6. Tel Aviv University research links childhood obesity to cancer risk
7. Marshall University scientist awarded NIH grant for lung cancer research
8. University of Texas Medical Branch to study hospital readmission
9. Oxford University Press acquires joint ownership of Journal of Surgical Case Reports
10. Tannins in sorghum and benefits focus of university, USDA study
11. ASHA grant funds cutting-edge AIDS research at Tel Aviv University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon ... this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay ... post about women’s hair loss. Although hair transplant procedures can be seen as more ... or genetics can be two reasons a woman may see her hair thinning. , ...
(Date:3/28/2017)... ... 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. ... that his parents and teachers had asked of him that he had neglected to do, ... defy the Almighty Creator. There were some who would have felt themselves to be special ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. ... smile makeovers without requiring a referral. Trimble Dental offers a variety of ... dentistry and dental implants. Whether patients have discolored, crooked or missing teeth in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... to the OSEHRA popHealth Community in 2014. It is the culmination ... the Developer Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 ... attention to these four stocks: The Medicines Co. ... Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals Inc. ... in the Generic Drugs space which is governed ... The key growth drivers for the industry are wholesalers, ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
(Date:3/27/2017)... SINGAPORE , March 27, 2017 ... a digital health and data analytics company, signed ... collaborations for improving healthcare delivery in the region. ... Institute for Global Health Research and Technology (BIGHEART) ... relationship on several topics related to healthcare IT ...
Breaking Medicine Technology: